Author Question: Suppose that a monopolistically competitive firm is in long-run equilibrium. The firm's demand curve ... (Read 162 times)

anshika

  • Hero Member
  • *****
  • Posts: 510
Suppose that a monopolistically competitive firm is in long-run equilibrium. The firm's demand curve is tangent to its average cost curve at Q = 25 . Average cost is minimized at Q = 35, where average cost is 50 . Which of the following is true?
 a. This firm charges 50 for the good.
  b. This firm charges more than 50 for the good.
  c. This firm charges less than 50 for the good.
  d. The firm has excess capacity at all output levels greater than 35 units.
  e. Average cost is 50 at the profit-maximizing output level.

Question 2

Sally, Kelly, and Debbie are roommates deciding on how many cats they want in the apartment. Sally prefers three cats to two cats to one cat, Kelly prefers two to one to three, and Debbie prefers one to two to three. If they decide by majority vote (one versus two, two versus three, and so on), how many cats will they get?
 a. none
  b. one
  c. two
  d. three
  e. the answer cannot be determined from the information given



Animal_Goddess

  • Sr. Member
  • ****
  • Posts: 339
Answer to Question 1

B

Answer to Question 2

C



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

People with high total cholesterol have about two times the risk for heart disease as people with ideal levels.

Did you know?

Common abbreviations that cause medication errors include U (unit), mg (milligram), QD (every day), SC (subcutaneous), TIW (three times per week), D/C (discharge or discontinue), HS (at bedtime or "hours of sleep"), cc (cubic centimeters), and AU (each ear).

Did you know?

Human kidneys will clean about 1 million gallons of blood in an average lifetime.

Did you know?

The U.S. Preventive Services Task Force recommends that all women age 65 years of age or older should be screened with bone densitometry.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library